Monitor upcoming clinical data milestones in 2026 and track sequential revenue growth of KOMZIFTI as indicators of commercial success, while watching cash burn rate given the significant increase in operating expenses.
KURA drugs
KURA drug pipeline →How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Mar 5 $8.51entry
- T+1 · 9mo ago +5.29%α +6.60% · $8.96
- T+5 · 8mo ago +3.88%α +6.12% · $8.84
- T+20 · 8mo ago +1.18%α +4.96% · $8.61
- T+60 · 6mo ago +6.17%α −5.13% · $9.04
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Kura Oncology reported its first commercial revenue of $2.1 million from KOMZIFTI, its newly approved AML drug, in Q4 2025. Despite this milestone, the company reported a significant net loss increase to $81 million due to higher R&D and commercialization expenses. The company maintains a strong cash position of $667.2 million and anticipates $180 million in collaboration payments.
Key Financial Metrics
Key Facts
- Generated $2.1 million in net product revenue from KOMZIFTI in Q4 2025 (first five weeks of sales)
- Net loss increased to $81 million in Q4 2025 from $19.2 million in Q4 2024
- Cash position of $667.2 million as of December 31, 2025
- Anticipates $180 million in collaboration payments from Kyowa Kirin
- R&D expenses increased to $64.4 million from $52.3 million year-over-year
Financial Impact
Q4 2025 net loss of $81 million on $17.3 million in total revenue
Segment Breakdown
| Segment | Revenue | Growth |
|---|---|---|
| Product revenue, net | $2.1M | Not reported |
| Collaboration revenue | $15.2M | -71.8% |
Risk Factors
- High cash burn rate with increasing R&D and commercialization expenses
- Limited commercial track record with KOMZIFTI revenue based on only five weeks of sales
- Dependence on anticipated $180 million in future collaboration payments
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-092465 |
| Document: kura-20260305.htm | 0001193125-26-092465 |
| Document: 0001193125-26-092465-index-headers.html | 0001193125-26-092465 |
| Document: 0001193125-26-092465-index.html | 0001193125-26-092465 |
| Document: 0001193125-26-092465.txt | 0001193125-26-092465 |
Track record
29 reports on KURA
6 of 9 bullish or bearish reports moved the stock their way by T+60. Best: +52.28% at T+60 after the Jun 3, 2026 report. 10 of 14 went positive at some point.
Filters
- Nov 16, 2026today Insider Buy Bullish 5/10 Entry $7.15 Now $7.09 −0.84% settles Feb 16
- Nov 16, 2026today 144 Neutral 3/10 Entry $7.15 Now $7.09 −0.84% settles Feb 16
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $7.15 Now $7.09 −0.84% settles Feb 16
- Nov 10, 20266d ago S-3ASR Neutral 4/10 Entry $7.73 Now $7.09 −8.28% settles Feb 9
- Nov 10, 20266d ago Press Release Neutral 5/10 Entry $7.73 Now $7.09 −8.28% settles Feb 9
- Nov 4, 202612d ago Press Release Neutral 4/10 Entry $7.61 Now $7.09 −6.83% settles Feb 2
- Sep 29, 20266w ago Insider Cluster Bearish 5/10 Entry $10.71 Now $7.09 +33.80% settles Dec 24
- Sep 29, 20266w ago Press Release Bullish 6/10 Entry $10.81 Now $7.09 −34.38% settles Dec 23
- Sep 9, 20269w ago 8-K Bullish 6/10 Entry $12.09 Now $7.09 −41.36% settles Dec 3
- Sep 8, 20269w ago 8-K Neutral 2/10 Entry $12.52 Now $7.09 −43.37% settles Dec 2
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers